Re:: Wolfe et al.: Do rhematology cost-effectiveness analyses make sense?

被引：7

作者：

Brennan, A ^{[1
]}

Bansback, N ^{[1
]}

机构：

[1] Univ Sheffield, Sch Hlth & Related Res, Sheffield S10 2TN, S Yorkshire, England

来源：

RHEUMATOLOGY | 2004年 / 43卷 / 05期

关键词：

D O I：

10.1093/rheumatology/keh096

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：677 / 678

页数：2

共 7 条

[1] Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK [J].

Brennan, A ;

Bansback, N ;

Reynolds, A ;

Conway, P .

RHEUMATOLOGY, 2004, 43 (01) :62-72

[2]

*BRIT SOC RHEUM, 2001, GUID PRESCR TNF ALPH

[3] Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden [J].

Geborek, P ;

Crnkic, M ;

Petersson, IF ;

Saxne, T .

ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (09) :793-798

[4] Etanercept therapy in rheumatoid arthritis - A randomized, controlled trial [J].

Moreland, LW ;

Schiff, MH ;

Baumgartner, SW ;

Tindall, EA ;

Fleischmann, RM ;

Bulpitt, KJ ;

Weaver, AL ;

Keystone, EC ;

Furst, DE ;

Mease, PJ ;

Ruderman, EM ;

Horwitz, DA ;

Arkfeld, DG ;

Garrison, L ;

Burge, DJ ;

Blosch, CM ;

Lange, MLM ;

McDonnell, ND ;

Weinblatt, ME .

ANNALS OF INTERNAL MEDICINE, 1999, 130 (06) :478-+

[5] Assessing quality in decision analytic cost-effectiveness models - A suggested framework and example of application [J].

Sculpher, M ;

Fenwick, E ;

Claxton, K .

PHARMACOECONOMICS, 2000, 17 (05) :461-477

[6] A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate [J].

Weinblatt, ME ;

Kremer, JM ;

Bankhurst, AD ;

Bulpitt, KJ ;

Fleischmann, RM ;

Fox, RI ;

Jackson, CG ;

Lange, M ;

Burge, DJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (04) :253-259

[7]

WOLFE F, 2003, RHEUMATOLOGY AD 1001

← 1 →